Analysts expect Heron Therapeutics Inc (NASDAQ:HRTX) to report ($0.47) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Heron Therapeutics’ earnings, with estimates ranging from ($0.60) to ($0.29). Heron Therapeutics reported earnings per share of ($0.77) during the same quarter last year, which suggests a positive year over year growth rate of 39%. The firm is expected to issue its next quarterly earnings report on Monday, November 5th.
According to Zacks, analysts expect that Heron Therapeutics will report full-year earnings of ($2.19) per share for the current financial year, with EPS estimates ranging from ($2.56) to ($1.81). For the next fiscal year, analysts expect that the business will report earnings of ($0.61) per share, with EPS estimates ranging from ($1.48) to $0.45. Zacks’ EPS calculations are an average based on a survey of research analysts that cover Heron Therapeutics.
Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.68) by $0.14. Heron Therapeutics had a negative net margin of 411.41% and a negative return on equity of 112.35%. The company had revenue of $17.28 million during the quarter, compared to analyst estimates of $12.82 million. During the same quarter last year, the business posted ($0.80) EPS. Heron Therapeutics’s quarterly revenue was up 103.1% compared to the same quarter last year.
In other Heron Therapeutics news, VP Kimberly Manhard sold 6,000 shares of the firm’s stock in a transaction on Monday, October 1st. The shares were sold at an average price of $32.07, for a total value of $192,420.00. Following the completion of the transaction, the vice president now directly owns 6,000 shares of the company’s stock, valued at approximately $192,420. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Kevin C. Tang sold 2,695,000 shares of the firm’s stock in a transaction on Wednesday, September 12th. The shares were sold at an average price of $35.75, for a total transaction of $96,346,250.00. The disclosure for this sale can be found here. 16.20% of the stock is currently owned by insiders.
A number of large investors have recently made changes to their positions in HRTX. Wells Fargo & Company MN boosted its holdings in Heron Therapeutics by 86.6% in the 1st quarter. Wells Fargo & Company MN now owns 60,545 shares of the biotechnology company’s stock valued at $1,670,000 after purchasing an additional 28,095 shares during the period. Northern Trust Corp boosted its holdings in Heron Therapeutics by 15.7% in the 1st quarter. Northern Trust Corp now owns 628,068 shares of the biotechnology company’s stock valued at $17,335,000 after purchasing an additional 85,109 shares during the period. BlackRock Inc. boosted its holdings in Heron Therapeutics by 18.0% in the 1st quarter. BlackRock Inc. now owns 3,512,721 shares of the biotechnology company’s stock valued at $96,952,000 after purchasing an additional 535,285 shares during the period. New York State Common Retirement Fund boosted its holdings in Heron Therapeutics by 21.0% in the 1st quarter. New York State Common Retirement Fund now owns 58,800 shares of the biotechnology company’s stock valued at $1,623,000 after purchasing an additional 10,200 shares during the period. Finally, BNP Paribas Arbitrage SA boosted its holdings in Heron Therapeutics by 18.6% in the 1st quarter. BNP Paribas Arbitrage SA now owns 11,229 shares of the biotechnology company’s stock valued at $310,000 after purchasing an additional 1,761 shares during the period.
Shares of HRTX stock opened at $29.13 on Friday. Heron Therapeutics has a 12-month low of $14.40 and a 12-month high of $42.90. The company has a market cap of $2.28 billion, a PE ratio of 7.98 and a beta of 1.59.
About Heron Therapeutics
Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.